The United States Patent and Trademark Office (USPTO) has granted patent to BioAlliance Pharma SA for its product Sitavig. This patent covers the Sitavig tablet, its manufacturing process and its application for the treatment of recurrent labial herpes until 2027.

BioAlliance Pharma has conceived and developed Sitavig (mucoadhesive tablet containing acyclovir) for the treatment of labial herpes in immunocompetent patients presenting more than four episodes a year. Sitavig is an innovative mucoadhesive tablet to apply to the upper gum, allowing the delivery of very high concentrations of the active ingredient at the site of herpes infection, thus with a reinforced profile of efficacy.

“After the grant of a patent for Sitavig in Europe and in major Asian territories, this US grant gives BioAlliance a worldwide protection for its product,” declares Aude Michel, vice president, licensing and legal affairs, and European Patent Attorney of BioAlliance Pharma.

“We have obtained the receivability of Sitavig US registration file last May from the FDA (Food and Drug Administration). This strong US patent protection allows its commercialization in the best conditions, reinforcing the value of this asset,” added Judith Greciet, CEO of BioAlliance Pharma. “After a first license agreement with Teva for Israel and with a sales potential from $120 to $150 million, this product is becoming a suitable candidate to a license agreement, particularly in the United States.”

BioAlliance Pharma dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.